Latest news
Dr Vincent Ma: CTGTAC's 10-3 Vote on RP1/Nivo Is “Encouraging” - Targeted OncologyTargeted Oncology · Mon, 03 Aug 2026 19:37:20 GMTDermata Therapeutics, Inc. Revenue Breakdown – NASDAQ:DRMA - TradingViewTradingView · Thu, 30 Jul 2026 08:02:46 GMTDr Ma on the Rationale and Design of an Evaluation of KB707 in Advanced NSCLC - OncLiveOncLive · Mon, 27 Jul 2026 07:00:00 GMT